{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:04:15Z","timestamp":1784347455321,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106762","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T07:01:49Z","timestamp":1758178909000},"page":"106762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Suboptimal dose of approved disease modifying therapies in management of patients with multiple sclerosis: A systematic review"],"prefix":"10.1016","volume":"104","author":[{"given":"Sepideh","family":"Paybast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Baghalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106762_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106297","article-title":"Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for multiple sclerosis: an observational registry-based study","volume":"94","author":"Alroughani","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on Anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0003","article-title":"Progressive multifocal leukoencephalopathy with extended Natalizumab dosing","volume":"8","author":"Baldassari","year":"2018","journal-title":"Neurol Clin Pr."},{"key":"10.1016\/j.msard.2025.106762_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying Ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","article-title":"The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review","volume":"35","author":"Biolato","year":"2021","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2025.106762_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-023-12084-4","article-title":"COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients","volume":"271","author":"Bisecco","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0007","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended Interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211042458","article-title":"No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)","volume":"14","author":"Butzkueven","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0009","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/vaccines9070773","article-title":"Multiple Sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations","volume":"9","author":"Cabreira","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.msard.2025.106762_bib0010","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different Natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106762_bib0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2020.2950","article-title":"Efficacy and safety of 2 Fingolimod doses vs Glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis","volume":"78","author":"Cree","year":"2021","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for Trusted Systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2025.106762_bib0013","first-page":"1","article-title":"The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive Multiple sclerosis in Iran","author":"Darvishi","year":"2024","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"key":"10.1016\/j.msard.2025.106762_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106762_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1352458506071172","article-title":"An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis","volume":"13","author":"Di Rezze","year":"2007","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1380654","article-title":"Hypogammaglobulinemia and infections in patients with Multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 Multiple sclerosis patients","volume":"15","author":"Elgenidy","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0017","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national Burden of Neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0018","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3390\/cells10113177","article-title":"Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects","volume":"10","author":"Fischer","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.msard.2025.106762_bib0019","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200606","article-title":"Long-term treatment with ponesimod in relapsing-remitting multiple sclerosis","volume":"99","author":"Freedman","year":"2022","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106762_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13561-024-00478-7","article-title":"Cost-utility and Cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review","volume":"14","author":"Gallehzan","year":"2024","journal-title":"Health Econ. Rev."},{"key":"10.1016\/j.msard.2025.106762_bib0022","doi-asserted-by":"crossref","DOI":"10.18502\/cjn.v22i2.13339","article-title":"Alternate dosing of Fingolimod in relapsing-remitting multiple sclerosis: a systematic review","author":"Ghadiri","year":"2023","journal-title":"Curr J Neurol"},{"key":"10.1016\/j.msard.2025.106762_bib0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.14740\/jocmr3168w","article-title":"A multiple treatment comparison of eleven disease-modifying drugs used for multiple sclerosis","volume":"10","author":"Hamidi","year":"2018","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.msard.2025.106762_bib0024","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/nmt.15.42","article-title":"Progressive multifocal leukoencephalopathy associated to Natalizumab extended dosing regimen","volume":"5","author":"Herv\u00e1s-Garc\u00eda","year":"2015","journal-title":"Neurodegener. Dis. Manage"},{"key":"10.1016\/j.msard.2025.106762_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of Fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2025.106762_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines9010012","article-title":"Safety of newer disease modifying therapies in multiple sclerosis","volume":"9","author":"Jalkh","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.msard.2025.106762_bib0027","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J. Manage Care Spec. Pharm."},{"key":"10.1016\/j.msard.2025.106762_bib0028","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of Fingolimod, Dimethyl Fumarate and teriflunomide for Multiple sclerosis","volume":"90","author":"Kalincik","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106762_bib0029","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/brain\/awx185","article-title":"Towards personalized therapy for multiple sclerosis: prediction of individual treatment response","volume":"140","author":"Kalincik","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106762_bib0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in Multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2025.106762_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, Rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106762_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS. Med."},{"key":"10.1016\/j.msard.2025.106762_bib0033","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/CPJ.0000000000000434","article-title":"Effectiveness of alternative dose fingolimod for Multiple sclerosis","volume":"8","author":"Longbrake","year":"2018","journal-title":"Neurol Clin Pr."},{"key":"10.1016\/j.msard.2025.106762_bib0034","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00415-022-11408-0","article-title":"Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic","volume":"270","author":"Magro","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0035","first-page":"557","article-title":"P1083: fingolimod every-other-day as a possible strategy to overcome fingolimod-induced severe lymphopenia in MS patients","volume":"21","author":"Merlini","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0036","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/nmt-2021-0038","article-title":"Healthcare resource utilization and costs for extended interval dosing of Natalizumab in multiple sclerosis","volume":"12","author":"Moccia","year":"2022","journal-title":"Neurodegener. Dis. Manage"},{"key":"10.1016\/j.msard.2025.106762_bib0037","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jnnp-2021-326839","article-title":"Vaccination and Multiple sclerosis in the era of the COVID-19 Pandemic","volume":"92","author":"Monschein","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106762_bib0038","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.3390\/ijms25105353","article-title":"Clinical and immunological impact of Ocrelizumab extended interval dosing in multiple sclerosis: a single-center","volume":"25","author":"Nasello","year":"2024","journal-title":"Real-World Exp. Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106762_bib0039","article-title":"Long-term outcomes of Peginterferon Beta-1a in multiple sclerosis: results from the advance extension study","volume":"11","author":"Newsome","year":"2018","journal-title":"ATTAIN. Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0040","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/CON.0000000000001156","article-title":"Diagnosis of multiple sclerosis","volume":"28","author":"Oh","year":"2022","journal-title":"CONTIN.: Lifelong Learn. Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0041","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","article-title":"Real-world effectiveness of Natalizumab extended interval dosing in a French cohort","volume":"12","author":"Pelle","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106762_bib0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","article-title":"Safety and efficacy of extended versus standard interval dosing of natalizumab in Multiple sclerosis patients: a systematic review and meta-analysis","volume":"124","author":"Rabea","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2025.106762_bib0043","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-020-04629-6","article-title":"Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis\u2014a Portuguese cohort","volume":"42","author":"Ramos-Lopes","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106762_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577627","article-title":"Update on the management of Multiple sclerosis during the COVID-19 Pandemic and Post Pandemic: an international consensus statement","volume":"357","author":"Reyes","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106762_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614715","article-title":"Does extended interval dosing Natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study","volume":"12","author":"Riancho","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106762_bib0048","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/13524585211055593","article-title":"Stable multiple sclerosis patients on Anti-CD20 therapy should go on extended interval dosing\u2014\u201cyes","volume":"28","author":"Rolfes","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0049","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106762_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00338","article-title":"Treatment modifiers across different regimens of natalizumab Treatment in MS: an Italian real-world experience","volume":"21","author":"Ruggieri","year":"2024","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106762_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103480","article-title":"No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS","volume":"58","author":"Ryerson","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103287","article-title":"Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation","volume":"56","author":"Sahi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103287","article-title":"Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation","volume":"56","author":"Sahi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0054","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s10072-019-03959-4","article-title":"Four cases of Natalizumab-related PML: a less severe course in extended interval dosing?","volume":"40","author":"Scarpazza","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106762_bib0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med."},{"key":"10.1016\/j.msard.2025.106762_bib0056","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med."},{"key":"10.1016\/j.msard.2025.106762_bib0057","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106762_bib0058","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70445","article-title":"Comparative efficacy and safety of extended versus standard interval dosing of Natalizumab in relapsing-remitting multiple sclerosis patients: a multicenter analysis","volume":"31","author":"Sefero\u011flu","year":"2025","journal-title":"CNS. Neurosci. Ther."},{"key":"10.1016\/j.msard.2025.106762_bib0059","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106762_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0061","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative Safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106762_bib0062","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/1352458512472750","article-title":"Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia","volume":"19","author":"Tanaka","year":"2013","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0063","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI analysis group","volume":"45","year":"1995","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106762_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00351","article-title":"Extended interval dosing of natalizumab: more evidence in support","volume":"21","author":"Toljan","year":"2024","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106762_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-332119","article-title":"Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106762_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2024-000672","article-title":"Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study","volume":"6","author":"Tran","year":"2024","journal-title":"BMJ Neurol. Open."},{"key":"10.1016\/j.msard.2025.106762_bib0067","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0068","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0069","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106762_bib0070","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with Multiple sclerosis during the COVID-19 Pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0071","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of Multiple Sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0072","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and pathophysiology of Multiple sclerosis","volume":"28","author":"Ward","year":"2022","journal-title":"CONTIN.: Lifelong Learn. Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0073","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in Multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106762_bib0074","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2015.05.012","article-title":"Safety and efficacy of reduced fingolimod dosage treatment","volume":"285","author":"Yamout","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106762_bib0076","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.msard.2018.12.025","article-title":"Adherence to oral disease-modifying therapy in Multiple sclerosis patients: a systematic review","volume":"28","author":"Yoon","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106762_bib0077","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is it time for Ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 Pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106762_bib0078","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is it time for Ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 Pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2025.106762_bib0079","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1352458517694089","article-title":"Half-dose Fingolimod for treating relapsing-remitting multiple sclerosis: observational study","volume":"24","author":"Zecca","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106762_bib0080","article-title":"Incidence and risk of infection associated with fingolimod in patients with multiple sclerosis: a systematic review and meta-analysis of 8448 patients from 12 randomized controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106762_bib0081","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106762_bib0082","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000672","article-title":"Pharmacodynamics of natalizumab extended interval dosing in MS","volume":"7","author":"Zhovtis Ryerson","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:38:44Z","timestamp":1784345924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":82,"alternative-id":["S2211034825005048"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106762","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suboptimal dose of approved disease modifying therapies in management of patients with multiple sclerosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106762"}}